Trade Names:Ilaris- Injection, lyophilized powder for solution 180 mg (150 mg/mL after reconstitution)
Neutralizes the biologic activity of interleukin-1beta (IL-1beta) by binding to IL-1beta and blocking its interaction with IL-1 receptors.
Bioavailability is 70%; C max is 16 mcg/mL and T max is 7 days.
The Vd ss is 6.01 L in a 70 kg patient.
Half-life is 26 days
No formal studies have been conducted.
Hepatic Function ImpairmentNo formal studies have been conducted.
ChildrenT max is 2 to 7 days and half-life ranged from 22.9 to 25.7 days.
Treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome.
Standard considerations.
Subcutaneous Dose based on weight.
15 to 40 kg2 mg/kg
More than 40 kg150 mg
Subsequent doses given every 8 wk.
Children 4 yr of age and olderSubcutaneous Dose based on weight.
15 to 40 kg2 mg/kg; if response is not adequate, may increase to 3 mg/kg
More than 40 kg150 mg.
Subsequent doses given every 8 wk.
Store unopened vials in refrigerator, between 36° and 46°F. Do not freeze. Protect from light. After reconstitution, solution may be kept at room temperature if used within 60 min of reconstitution. Reconstituted solution should be refrigerated between 36° and 46°F and used within 4 h of reconstitution.
Increased risk of infection.
Live vaccinesMay decrease efficacy of live vaccines. Do not give concurrently.
CYP-450 substratesClosely monitor CYP-450 substrates with a narrow therapeutic index (eg, warfarin) after initiating canakinumab.
None well documented.
Headache (14%); vertigo (11%).
Nasopharyngitis (34%); rhinitis (17%); pharyngitis (11%).
Diarrhea (20%); nausea (14%); gastroenteritis (11%).
Mild injection-site reactions (9%).
Bronchitis (11%).
Influenza (17%); musculoskeletal pain, weight increased (11%).
MonitorDocument baseline disease state activity (eg, fatigue, fever, headache, painful joints or muscles, rash). Reassess periodically to document response to therapy. |
Category C .
Undetermined.
Safety and efficacy not established in children younger than 4 yr of age.
May result in an increase in malignancies.
Serious infections may occur. Monitor patient for signs and symptoms of infection (eg, cellulitis, persistent fever, sore throat). Discontinue therapy if a serious infection develops or is suspected.
Prior to initiating canakinumab, test for latent tuberculosis (TB). Treat patients testing positive in TB screening with standard medical therapy prior to treatment with canakinumab.
Do not give live vaccines concomitantly.
Copyright © 2009 Wolters Kluwer Health.